Related references
Note: Only part of the references are listed.TGFαL3-SEB fusion protein as an anticancer against ovarian cancer
Farajolah Maleki et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins
Zoleikha Goleij et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2020)
Growth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line
Farajolah Maleki et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
In Silico Analyses of Staphylococcal Enterotoxin B as a DNA Vaccine for Cancer Therapy
Abolfazl Jahangiri et al.
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS (2018)
Staggered Target SELEX, a novel approach to isolate non-cross-reactive aptamer for detection of SEA by apta-qPCR
Hamid Sedighian et al.
JOURNAL OF BIOTECHNOLOGY (2018)
DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice
Mahendra K. Bhopale et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2017)
TAT-BoNT/A(1-448), a novel fusion protein as a therapeutic agent: analysis of transcutaneous delivery and enzyme activity
Parvaneh Saffarian et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2016)
Shiga toxins: from structure and mechanism to applications
Yau Sang Chan et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2016)
Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen
Forough Yousefi et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2016)
Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit
Philipp Emanuel Geyer et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy
Changyou Zhan et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
A new delivery system for auristatin in STxB-drug conjugate therapy
Cornelie Batisse et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25+ cells
Jaclyn Stromp Peraino et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
H. Miles Prince et al.
EXPERT OPINION ON ORPHAN DRUGS (2014)
Failure of Manganese to Protect from Shiga Toxin
Marsha A. Gaston et al.
PLOS ONE (2013)
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
X. Sui et al.
CELL DEATH & DISEASE (2013)
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Gabriel Tinoco et al.
JOURNAL OF CANCER (2013)
Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review
Amanda D. Hutchinson et al.
CANCER TREATMENT REVIEWS (2012)
Development of a Diphtheria Toxin Based Antiporcine CD3 Recombinant Immunotoxin
Zhirui Wang et al.
BIOCONJUGATE CHEMISTRY (2011)
Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit
Matthias Maak et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Shiga toxin and its use in targeted cancer therapy and imaging
Nikolai Engedal et al.
MICROBIAL BIOTECHNOLOGY (2011)
Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis
David Johansson et al.
BMC CANCER (2009)
Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines
David Johansson et al.
CANCER BIOLOGY & THERAPY (2006)
Targeted therapy of cancer: New prospects for antibodies and immunoconjugates
Robert M. Sharkey et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Cholera and Shiga toxin B-subunits: thermodynamic and structural considerations for function and biomedical applications
DG Pina et al.
TOXICON (2005)
Verotoxin induces rapid elimination of human renal tumor xenografts in scid mice
S Ishitoya et al.
JOURNAL OF UROLOGY (2004)
A flexible peptide linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion protein
WG Hu et al.
JOURNAL OF BIOTECHNOLOGY (2004)
Extension of juxtamembrane domain of diphtheria toxin receptor arrests translocation of diphtheria toxin fragment A into cytosol
T Takahashi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Use of bacteria as anticancer agents
KK Jain
EXPERT OPINION ON BIOLOGICAL THERAPY (2001)
The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
N Haicheur et al.
JOURNAL OF IMMUNOLOGY (2000)
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: A potential vector for delivering heterologous proteins to neurons
JW Francis et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Clinical significance of Verocytotoxin-producing Escherichia coli O157
H Chart
WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY (2000)
Share Paper
